NCT06305910View on ClinicalTrials.gov

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

September 15, 2025

Study Completion Date

January 15, 2027

Conditions
Diffuse Midline Glioma, H3 K27M-MutantRecurrent High Grade Glioma
Interventions
DRUG

Treatment with CD200AR-L

Treatment with CD200AR-L (up to 3 dose levels of CD200AR-L with a Dose Level -1 in the event of toxicity) with fixed doses of GBM6-AD vaccine. Each patient will also be given topical imiquimod and a single dose of 300cGy re-irradiation.

Trial Locations (1)

55404

RECRUITING

Children's Minnesota, Minneapolis

Sponsors

Lead Sponsor

OX2 Therapeutics
All Listed Sponsors
lead

OX2 Therapeutics

INDUSTRY